AbbVie Inc (ABBV)

65.84
0.40 0.61
NYSE : Health Care
Prev Close 65.44
Open 65.44
Day Low/High 65.43 / 66.26
52 Wk Low/High 55.06 / 68.12
Volume 4.68M
Avg Volume 6.02M
Exchange NYSE
Shares Outstanding 1.59B
Market Cap 104.37B
EPS 3.60
P/E Ratio 12.99
Div & Yield 2.56 (3.90%)

Latest News

AbbVie Presents Pivotal Phase 3 Data On Investigational Treatment Elagolix At The World Congress On Endometriosis

AbbVie Presents Pivotal Phase 3 Data On Investigational Treatment Elagolix At The World Congress On Endometriosis

- Primary and secondary efficacy and safety data to be presented from two pivotal Phase 3 studies evaluating the use of elagolix in endometriosis-associated pain

AbbVie Stock Lower on Humira Patent Ruling

AbbVie Stock Lower on Humira Patent Ruling

The drug is responsible for more than 60% of AbbVie's top line.

AbbVie, Broadcom, Enbridge Energy Partners, Commercial Vehicle Group: 'Mad Money' Lightning Round

AbbVie, Broadcom, Enbridge Energy Partners, Commercial Vehicle Group: 'Mad Money' Lightning Round

Jim Cramer is bullish on AbbVie, Broadcom, Enbridge Energy Partners, and Commercial Vehicle Group.

Industrials Are Stalling, Techs Are Roaring: Cramer's 'Mad Money' Recap (Monday 5/15/17)

Industrials Are Stalling, Techs Are Roaring: Cramer's 'Mad Money' Recap (Monday 5/15/17)

Jim Cramer says investors are migrating toward sectors likely to have the biggest upside in the second half.

AbbVie Announces Positive Phase 2 Study Results For Upadacitinib (ABT-494), An Investigational JAK1-Selective Inhibitor, In Crohn's Disease

AbbVie Announces Positive Phase 2 Study Results For Upadacitinib (ABT-494), An Investigational JAK1-Selective Inhibitor, In Crohn's Disease

- Phase 2 study showed positive results in a moderately to severely active Crohn's disease patient population, the majority of whom had previously failed two or more biologics

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.

AbbVie Demonstrates Leadership In Gastroenterology And Hepatology With New Data And Late-Breaking Studies To Be Presented At Digestive Disease Week®

AbbVie Demonstrates Leadership In Gastroenterology And Hepatology With New Data And Late-Breaking Studies To Be Presented At Digestive Disease Week®

- Phase 2 late-breaking study evaluates upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in patients with moderately to severely active Crohn's disease, the majority of whom had failed two or more biologics

Earnings: Assessing 3 Biotech Bellwethers

Earnings: Assessing 3 Biotech Bellwethers

How did Celgene, AbbVie and Gilead fare last quarter?

Between Amazon and Alphabet; Oil Dominoes: Jim Cramer's View

Between Amazon and Alphabet; Oil Dominoes: Jim Cramer's View

Cramer shares his views on which is better: Amazon or Alphabet, and discusses the domino effect when oil falls.

Domino Effect of Falling Oil Prices: Cramer's 'Mad Money' Recap (Thursday 4/27/17)

Domino Effect of Falling Oil Prices: Cramer's 'Mad Money' Recap (Thursday 4/27/17)

Jim Cramer says this market is strong enough to withstand falling oil prices and a tax plan that will face a lot of obstacles.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Cramer: When Oil Falls, These Dominoes Get Hit

Cramer: When Oil Falls, These Dominoes Get Hit

It doesn't look like Washington will be much help.

S&P 500, Dow Hold Slight Gains as Positive Earnings Counter Oil Slump

S&P 500, Dow Hold Slight Gains as Positive Earnings Counter Oil Slump

Stocks hold onto slight to modest gains Thursday afternoon after positive earnings help to offset a slump in crude oil prices and a decline in energy names.

AbbVie Is Flexing Its Abs

AbbVie Is Flexing Its Abs

ABBV is now set up well for more upside.

Stocks Turn Mixed in Face of Crude Oil Slump

Stocks Turn Mixed in Face of Crude Oil Slump

Stocks turn mixed on Thursday after a slump in crude oil prices, and a decline in energy names, snarl earlier upward momentum.

Stock Futures Higher as Positive Earnings Offset Weaker Durable Goods Orders

Stock Futures Higher as Positive Earnings Offset Weaker Durable Goods Orders

Stock futures creep higher on Thursday as Wall Street returns its attention to positive earnings for market direction after a day focused on the White House's tax reform plans.

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures rise modestly Thursday after Donald Trump's tax plan fails to deliver any surprises but instead raises many more questions.

Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids

Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids

Nobody shows their hand in negotiations. Why should government? This new tax plan must go to Congress.

Surveying the NASH Drug Landscape

Surveying the NASH Drug Landscape

Biotech investors should keep a close eye on the progress in this huge potential market.

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.

EQT Midstream Partners, AbbVie, Blackstone Group: 'Mad Money' Lightning Round

EQT Midstream Partners, AbbVie, Blackstone Group: 'Mad Money' Lightning Round

Jim Cramer is bullish on EQT Midstream Partners, AbbVie, Blackstone Group, and Core Civic.

Here's Why You Should Hope for Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)

Here's Why You Should Hope for Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)

Jim Cramer looks at how the French elections are smacking the U.S stock markets. Plus, he has the week-ahead game plan for oil and stocks.

AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate In Chronic Hepatitis C Patients With Compensated Cirrhosis

AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate In Chronic Hepatitis C Patients With Compensated Cirrhosis

- New data demonstrated high SVR(12) rates across compensated cirrhotic patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C virus (HCV) infection with 12 weeks of treatment(1)

Gilead, Pfizer, AbbVie Win From Lilly's Loss

Gilead, Pfizer, AbbVie Win From Lilly's Loss

The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.